Total
0
Shares
medical xray
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Lobe Sciences has announced that Dr. Benjamin Kelmendi has been appointed to the company’s scientific advisory board
  • Dr. Kelmendi is an assistant professor of psychiatry at the Yale University School of Medicine and the co-founder of the Yale Psychedelic Science Group
  • He leads a research program focused on the therapeutic potential of psychedelic medicines across a range of psychiatric diagnoses
  • Lobe is a life sciences company focused on psychedelic medicines
  • Lobe Sciences (LOBE) is steady, holding at $0.135 per share at market close

Dr. Benjamin Kelmendi, an assistant professor of psychiatry at Yale University, has been appointed to the company’s scientific advisory board.

Dr. Kelmendi is also the co-founder of the Yale Psychedelic Science Group.

He is a board-certified psychiatrist and brings clinical expertise in post-traumatic stress disorder, depression, obsessive-compulsive disease.

Philip Young, CEO and director of Lobe Sciences, commented,

“We are extremely pleased to welcome Ben to our Scientific Advisory Board. Dr. Kelmendi will add significant relevant experience to the team as we move through preclinical studies into human clinical trials.”

Dr. Kelmendi leads a research program focused on the therapeutic potential of psychedelic medicines across a range of psychiatric diagnoses.

“The re-emergence of psychedelic medicine as a respected area of research has undergone a protean trajectory,” he commented.

“I am excited by the renewed interest in the potential of psychedelic substances, both as therapeutic agents and as tools to provide insight into the human brain and mind’s inner workings. I look forward to working with the advisory board and the Lobe team as we all work together to ethically develop psychedelic therapies for mental illness,” he added.

Lobe is a life sciences company focused on psychedelic medicines.

The company, through collaborations with industry-leading partners, is engaged in drug research and development.

Lobe Sciences (LOBE) is steady, holding at $0.135 per share at market close. 

More From The Market Herald

" Levitee Labs (CSE:LVT) enters into credit facility for up to $12 Million

Levitee Labs Inc. (LVT) has entered into a financing agreement for up to $12 million to fund further business expansion.
Small Pharma - Chief Medical and Scientific Officer, Carol Routledge.

" Small Pharma (TSXV:DMT) granted fast-track designation for DMT-assisted therapy

Small Pharma (DMT) has been granted fast-track designation in the U.K. for DMT-assisted therapy for major depressive disorder.

" Psyched Wellness (CSE:PSYC) shares preliminary data from amanita muscaria mushroom study

Psyched Wellness Ltd. (PSYC) has released its preliminary data revealing a potential new functional property and health benefit of AME-1.
Field Trip Health - President, Hannan Fleiman.

" Field Trip Health (TSX:FTRP) announces three new therapy centers

Field Trip Health (FTRP) is announcing new psychedelic-assisted therapy centers in Seattle, Vancouver and Fredericton.